收藏切换
New requirements and response strategies for principal investigators and clinical trial institutions under the revised Good Clinical Practice guidelines
收藏切换
Luo-xi YANG1, 2, Liang PAN1, Chun-yan GAN1, Li ZHANG1, Ji-yin ZHOU3, *
Chinese Journal of New Drugs | 2026, 35(19) : 2028 - 2037
Less
收藏切换
Chinese Journal of New Drugs | 2026, 35(19): 2028-2037
New requirements and response strategies for principal investigators and clinical trial institutions under the revised Good Clinical Practice guidelines
Full
Luo-xi YANG1, 2, Liang PAN1, Chun-yan GAN1, Li ZHANG1, Ji-yin ZHOU3, *
Affiliations
  • 1 Clinical Trial Center, Deyang People’s Hospital, Deyang 618000, China
  • 2 School of Medicine, University of Electronic Science and Technology of China, Chengdu 610054, China
  • 3 Clinical Medical Research Center, the Second Affiliated Hospital of Army Medical University, Chongqing 400037, China
Published: 2026-10-15 doi: 10.20251/j.cnki.1003-3734.2026.19.002
Outline
收藏切换
Objective:

To analyze the new requirements imposed on principal investigators and clinical trial institutions by the revised Good Clinical Practice (GCP) guidelines, and to explore the challenges currently facing the industry along with corresponding response strategies.

Methods:

Through an in-depth interpretation of the revised GCP provisions and a comparative analysis with the 2020 version, integrated with the core principles of ICH E6(R3), this study examined compliance and the current status from the perspectives of legal liability delineation, participant protection, data integrity, and quality management system development.

Results:

The legal status of the principal investigator as the “ultimate responsible party at the clinical trial site” was established, and it was proposed that clinical trial institutions should build and ensure the effective operation of a full process quality management system. In addition, an intelligent management pathway was identified, embedding digital tools into management processes to address practical challenges including technical barriers, cost investments, and cognitive biases.

Conclusion:

The implementation of the revised GCP signifies a shift in China’s clinical trial management from the former “compliance oriented” approach toward “quality-by-design” and “risk-based” approaches. Principal investigators and clinical trial institutions should leverage digital transformation and the co-evolution of management paradigms to create an intelligent quality ecosystem, achieving a substantial leap in clinical trial performance while maintaining full regulatory compliance.

Good Clinical Practice  /  principal investigator  /  clinical trial institution  /  quality management  /  response strategies
杨洛浠, 潘亮, 甘春燕, 张丽, 周吉银. 新版《药物临床试验质量管理规范》对主要研究者和临床试验机构的新要求及其应对措施. 中国新药杂志, 2026 , 35 (19) : 2028 -2037 . DOI: 10.20251/j.cnki.1003-3734.2026.19.002
Luo-xi YANG, Liang PAN, Chun-yan GAN, Li ZHANG, Ji-yin ZHOU. New requirements and response strategies for principal investigators and clinical trial institutions under the revised Good Clinical Practice guidelines[J]. Chinese Journal of New Drugs, 2026 , 35 (19) : 2028 -2037 . DOI: 10.20251/j.cnki.1003-3734.2026.19.002
Year 2026 volume 35 Issue 19
59
12
Cite this Article
BibTeX
Article Info
doi: 10.20251/j.cnki.1003-3734.2026.19.002
  • Receive Date:2026-07-27
  • Online Date:2026-10-29
  • Published:2026-10-15
Article Data
Affiliations
History
  • Received:2026-07-27
Funding
Affiliations
    1 Clinical Trial Center, Deyang People’s Hospital, Deyang 618000, China
    2 School of Medicine, University of Electronic Science and Technology of China, Chengdu 610054, China
    3 Clinical Medical Research Center, the Second Affiliated Hospital of Army Medical University, Chongqing 400037, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/10.20251/j.cnki.1003-3734.2026.19.002
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT